Permanent URI for this collection
Peter Doshi is an associate professor of pharmaceutical health services research in the School of Pharmacy and senior editor at The BMJ. His research focuses on policies related to drug safety and effectiveness evaluation in the context of regulation, evidence-based medicine, and debates over access to data. Doshi also has strong interests in journalism as a vehicle for encouraging better practice and improving the research enterprise.
Browse
Recent Submissions
Item Crowdfunding investigative journalism at The BMJ(BMJ Publishing Group, 2022-03-29) Coombes, Rebecca (Magazine editor); Doshi, PeterThe BMJ is now more than a scholarly journal, and for the past decade we have pursued investigative journalism as a powerful lever for improving health by exposing failings in the system. Over the past year we have substantially expanded our coverage, publishing 16 investigative stories (bmj.com/investigations), including a series that won a British Journalism Award, and worked with a greater number of international journalists. We have reported the disclosures of a whistleblower working on the Pfizer covid-19 vaccine trial, a story that unexpectedly led us to confront Facebook over the way it deals with misinformation on its platform. We have probed the implications of mRNA instability in vaccines and asked serious questions about Russia’s Sputnik vaccine. Beyond covid, we have tackled concerns in global health, including polio eradication, and asked whether health institutions should still be investing in fossil fuels.Item Assessing Muscle-Related Adverse Events in Randomized Trials of Statins.(Springer Nature, 2022-03-16) Doshi, Peter; Hong, Kyungwan; Tanveer, Sarah; Jefferson, TomItem Evaluation of Publicly Available Information on Sex-Related Differences in the Efficacy and Safety of Newly Approved Medications.(2022-02-08) Hong, Kyungwan; Tanveer, Sarah; Hassan, Hazem E; Doshi, PeterItem Covid-19 vaccines and treatments: we must have raw data, now(BMJ, 2022-01-19) Doshi, Peter; Godlee, Fiona; Abbasi, KamranItem Determining the Infectious Potential of Individuals With Positive Reverse-Transcription Polymerase Chain Reaction Severe Acute Respiratory Syndrome Coronavirus 2 Tests.(Oxford University Press, 2021-12-06) Doshi, Peter; Powers, John HItem Opinion | Coronavirus Vaccine Trials Could Suffer From Shortcuts: These Coronavirus Trials Don’t Answer the One Question We Need to Know(The New York Times Company, 2020-09-22) Doshi, Peter; Topol, EricItem How to Fix the Coronavirus Vaccine Rollout: Don’t Pressure the Vaccine-Hesitant(The New York Times Company, 2021-01-07) Doshi, PeterItem Evaluating covid-19 vaccine efficacy and safety in the post-authorisation phase.(BMJ Publishing Group, 2021-12-23) Prugger, Christof; Spelsberg, Angela; Keil, Ulrich; Erviti, Juan; Doshi, PeterItem Rapid Response to Gupta and colleagues' comments on "Will covid-19 vaccines save lives? Current trials aren’t designed to tell us"(BMJ Publishing Group, 2020-04-08) Doshi, PeterItem Did the FDA understaff its review of the Pfizer/BioNTech vaccine?(STAT, 2020-12-17) Doshi, Peter; Herder, MatthewItem How to Expand Access to COVID Vaccines without Compromising the Science: Emergency use authorizations by the FDA are not ideal(Springer Nature, 2020-12-17) Doshi, Peter; Light, DonaldItem Vaccine mandates: a new form of ‘institutional segregation’(Tribune Publishing, 2021-08-31) Doshi, Peter; Bhargava, AditiItem How clinically serious is SARS-CoV-2 infection for children and young adults?: Rapid response to: Covid-19: re-opening universities is high risk(BMJ Publishing Group, 2020-10-12) Doshi, Peter; Tanveer, SarahItem Peter Doshi: Pfizer and Moderna’s “95% effective” vaccines—let’s be cautious and first see the full data(BMJ Publishing Group, 2020-11-26) Doshi, PeterItem Peter Doshi: Pfizer and Moderna’s “95% effective” vaccines—we need more details and the raw data(BMJ Publishing Group, 2021-01-04) Doshi, PeterItem Inaccurate Statement [regarding to statement “Clinical trials have shown that the vaccines authorized for use in the US are highly effective against COVID-19 infection, severe illness, and death.”](American Medical Association, 2021-03-02) Doshi, PeterItem Covid-19 vaccines for children: hypothetical benefits to adults do not outweigh risks to children(BMJ Publishing Group, 2021-07-13) Doshi, PeterItem Does the FDA think these data justify the first full approval of a covid-19 vaccine?(BMJ Publishing Group, 2021-08-23) Doshi, PeterItem The End of the Pandemic Will Not Be Televised(BMJ Publishing Group, 2021-12-14) Robertson, David; Doshi, PeterItem Covid-19: Spreading vaccine "misinformation" puts licence at risk, US boards tell physicians(BMJ Publishing Group, 2021-10-01) Doshi, Peter